Precision Medicine
Its new risk score harnesses clinically-validated information from non-clinical settings, enabling health systems to better manage their 30-day readmission risks.
Actionable insights and intelligent health care experiences lead to personalized care and improved operations for providers.
Helix has closed a $200 million financing round and said it plans to expand its personal genomics marketplace to accelerate consumer adoption of genomics.
The San Carlos, California-based startup launched the Helix marketplace in July 2017 to collects and sequence a DNA sample once, and then store and protects a customer’s data so they can access additional DNA-powered products and services from the Helix store without providing another saliva sample.
[Also: 23andMe lands $250 million to expand do-it-yourself genetics testing]
Helix CEO Robin Thurston said the financing will enable it to expand its health-related product offerings as it competes with other genetics companies, such as 23andMe and AncestryDNA.
Thurston added that Helix also works with research partners such as the Healthy Nevada Project on community health projects built on Helix Exome platform.
The Helix store includes 35 products from 20 partners and that number is expected to grow to more 50 products in 2018 with major launches including new products from partners such as Mayo Clinic.
[Also: Microsoft, Google invest in precision medicine startup DNAnexus]
Helix has sealed deals with 47 companies to run tests on the Helix platform. Tests are available for $20 and others cost hundreds of dollars.
DFJ Growth, with participation from all its founding investors, which include Illumina, Kleiner Perkins Caufield Byers, Mayo Clinic, Sutter Hill Ventures, and Warburg Pincus, led the funding round.
Barry Schuler, Partner at DFJ Growth and former chairman and CEO of America Online, will join the Helix Board of Directors.
Twitter: @Bernie_HITN
Email the writer: bernie.monegain@himssmedia.com
The new partnership aims to enable integration of genomic data across the EHR, making it easier for physicians to order specific tests for personalized medicine.
The technology could enable researchers to test drugs or treatments on a patient’s cells to avoid harmful, ineffective and costly options while determining personalized regimens.
The hospital says the TriNetX network gives its patients the chance to participate in clinical trials they otherwise might not know exist.
Experts will address a range of topics from current challenges to the future vision of precision medicine.
John Halamka and Paul Cerrato sift through the hope and the hype of personally-tailored care, spotlighting to real-world success stories while not ignoring some significant potential pitfalls along the way.
Highlights about the challenges and opportunities of precision medicine at this year’s health IT conference.
Taken together they represent an essential and very different way of thinking about the healthcare business model that exists today.